Breathalyzer Market Outlook:
Breathalyzer Market size was over USD 3.9 billion in 2025 and is estimated to reach USD 16.1 billion by the end of 2035, expanding at a CAGR of 17.1% during the forecast timeline, i.e., 2026-2035. In 2026, the industry size of breathalyzer is assessed at USD 4.5 billion.
The primary patient pool of the market contains people with alcohol and drug abuse disorders. According to a report from the World Health Organization (WHO), more than 400 million global residents, accounting for 7% of the world’s population aged 15 years and older, were living with alcohol use disorder (AUD) in 2024. Thus, considering the future impact of excessive consumption of these substances on overall health, worldwide governing authorities are implementing strict measures to combat the epidemic. In addition, these tools are utilized in patient management for several chronic ailments, including respiratory diseases, diabetes, and metabolic disorders, which is expanding the consumer base for this sector.
The rising cost of laboratory instruments and testing reagents inflates the overall payers’ pricing of diagnosing associated illnesses, particularly in emergency situations. Thus, the rapid and cost-effective testing solutions available in the market are gaining traction in the field of healthcare diagnostics. This can be exemplified by the comparative analysis of diagnostic costs between breath analysis and laboratory screening for diabetic ketoacidosis (DKA), where a study established an IoT-based breathalyzer prototype to be promisingly accurate while priced as low as USD 20.0, as per the 2022 NLM publication. This can be a cost-effective alternative to routine DKA screening, costing around USD 14.0 thousand.
